Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD33 antigen-armed antibody
- Development stage
- Preclinical
- Lead developer
- German Cancer Research Center
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-CD33 antigen-armed antibody (AgAb) is an experimental immunotherapy designed for the treatment of acute myeloid leukemia (AML). Developed by researchers at the German Cancer Research Center (DKFZ) and the University of Heidelberg, this construct consists of a monoclonal antibody targeting the CD33 antigen—a marker frequently overexpressed on AML blasts—fused with immunodominant epitopes from the Epstein-Barr virus (EBV). Upon binding to CD33, the AgAb is internalized via receptor-mediated endocytosis, and the viral epitopes are processed and presented on the cell surface through MHC class II molecules. This mechanism effectively "labels" the leukemia cells as virus-infected, allowing pre-existing EBV-specific memory CD4+ cytotoxic T cells (present in approximately 95% of the population) to recognize and lyse the malignant cells. This approach aims to overcome the low natural immunogenicity of AML by harnessing potent, established anti-viral immune responses.
- Other names
- CD33-AgAbCD-33-AgAbCD 33-AgAbCD33-targeted antigen-armed antibodyCD-33-targeted antigen-armed antibodyCD 33-targeted antigen-armed antibody
02
Targets
HLA-DR (Human leukocyte antigen DR)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on anti-CD33 antigen-armed antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD33 antigen-armed antibody.